Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease

Journal of Clinical Neuroscience

Volumn 19, Issue 3, 2012, Pages 343-348

  Cheshire, Perdita A ^a   Williams, David R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Dyskinesia; Levodopa; Parkinson's disease; Serotonin autoreceptor agonists

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MIRTAZAPINE; TANDOSPIRONE;

AUTOPSY; CLINICAL TRIAL (TOPIC); DOPAMINE METABOLISM; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DYSKINESIA; EXPERIMENTAL MODEL; HUMAN; NERVE FUNCTION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM;

ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIPARKINSON AGENTS; DOPAMINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; NEURONS; PARKINSON DISEASE; SEROTONIN;

EID: 84862783258     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2011.09.008     Document Type: Review

References (76)

1. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 2001 448 458
2. A. Schrag, M. Jahanshahi, and N. Quinn What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 69 2000 308 312
3. R.C. Dodel, K. Berger, and W.H. Oertel Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias Pharmacoeconomics 19 2001 1013 1038
4. J. Jankovic Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations Mov Disord 20 Suppl. 11 2005 S11 S16
5. S. Fahn, D. Oakes, and I. Shoulson Levodopa and the progression of Parkinson's disease N Engl J Med 351 2004 2498 2508
6. F. Grandas, M.L. Galiano, and C. Tabernero Risk factors for levodopa-induced dyskinesias in Parkinson's disease J Neurol 246 1999 1127 1133
7. A. Schrag, and N. Quinn Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study Brain 123 2000 2297 2305
8. F. Stocchi, M. Tagliati, and C.W. Olanow Treatment of levodopa-induced motor complications Mov Disord 23 Suppl. 3 2008 S599 S612
9. E. Wolf, K. Seppi, and R. Katzenschlager Long-term antidyskinetic efficacy of amantadine in Parkinson's disease Mov Disord 25 2010 1357 1363
10. O. Rascol, A. Lozano, and M. Stern Milestones in Parkinson's disease therapeutics Mov Disord 26 2011 1072 1082
11. H. Sawada, T. Oeda, and S. Kuno Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial PLoS ONE 5 2010 e15298
12. A. Thomas, D. Iacono, and A.L. Luciano Duration of amantadine benefit on dyskinesia of severe Parkinson's disease J Neurol Neurosurg Psychiatry 75 2004 141 143
13. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931-8.
14. O. Rascol, D.J. Brooks, and A.D. Korczyn A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 342 2000 1484 1491
15. R. Constantinescu, M. Romer, and M.P. McDermott Impact of pramipexole on the onset of levodopa-related dyskinesias Mov Disord 22 2007 1317 1319
16. J.G. Nutt Pharmacokinetics and pharmacodynamics of levodopa Mov Disord 23 Suppl. 3 2008 S580 S584
17. A. Antonini, and P. Odin Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease Parkinsonism Relat Disord 15 Suppl. 4 2009 S97 S100
18. M. Carta, H.S. Lindgren, and M. Lundblad Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats J Neurochem 96 2006 1718 1727
19. K. Buck, and B. Ferger Intrastriatal inhibition of aromatic amino acid decarboxylase prevents L-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats Neurobiol Dis 29 2008 210 220
20. W. Meissner, P. Ravenscroft, and R. Reese Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine Neurobiol Dis 22 2006 586 598
21. N. Pavese, A.H. Evans, and Y.F. Tai Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study Neurology 67 2006 1612 1617
22. US Department of Health EaW. Abnormal Involuntary Movements Scale. Guy W, editor. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
23. R. de la Fuente-Fernandez, V. Sossi, and Z. Huang Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain 127 2004 2747 2754
24. R. Arai, N. Karasawa, and M. Geffard Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase Brain Res 667 1994 295 299
25. H. Yamada, Y. Aimi, and I. Nagatsu Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats Neurosci Res 59 2007 1 7
26. R. Arai, N. Karasawa, and M. Geffard L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study Neurosci Lett 195 1995 195 198
27. T. Maeda, K. Nagata, and Y. Yoshida Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA Brain Res 1046 2005 230 233
28. H. Tanaka, K. Kannari, and T. Maeda Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 1999 631 634
29. H.S. Lindgren, D.R. Andersson, and S. Lagerkvist L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J Neurochem 112 2010 1465 1476
30. M.A. Cenci, and H.S. Lindgren Advances in understanding L-DOPA-induced dyskinesia Curr Opin Neurobiol 17 2007 665 671
31. K. Kannari, H. Tanaka, and T. Maeda Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation J Neurochem 74 2000 263 269
32. A. Lopez, A. Munoz, and M.J. Guerra Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum Neuroscience 103 2001 639 651
33. M. Parent, M.J. Wallman, and D. Gagnon Serotonin innervation of basal ganglia in monkeys and humans J Chem Neuroanat 41 2011 256 265
34. M.J. Wallman, D. Gagnon, and M. Parent Serotonin innervation of human basal ganglia Eur J Neurosci 33 2011 1519 1532
35. S. Navailles, and P. De Deurwaerdere Presynaptic control of serotonin on striatal dopamine function Psychopharmacology (Berl) 213 2011 213 242
36. P.C. Waldmeier Displacement of striatal 5-hydroxytryptamine by dopamine released from endogenous stores J Pharm Pharmacol 37 1985 58 60
37. J.P. Finn 3rd, and R.H. Edwards Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2 J Biol Chem 272 1997 16301 16307
38. M. Carta, T. Carlsson, and D. Kirik Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 130 2007 1819 1833
39. S. Navailles, B. Bioulac, and C. Gross Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease Neurobiol Dis 38 2010 136 143
40. D. Rylander, M. Parent, and S.S. O'Sullivan Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann Neurol 68 2010 619 628
41. B.Y. Zeng, M.M. Iravani, and M.J. Jackson Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiol Dis 40 2010 599 607
42. S.J. Gil, C.H. Park, and J.E. Lee Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats Brain Res Bull 84 2011 151 156
43. A. Munoz, Q. Li, and F. Gardoni Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain 131 2008 3380 3394
44. K.L. Eskow, V. Gupta, and S. Alam The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy Pharmacol Biochem Behav 87 2007 306 314
45. M. Tomiyama, T. Kimura, and T. Maeda A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease Neurosci Res 52 2005 185 194
46. K.B. Dupre, K.L. Eskow, and G. Negron The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat Brain Res 1158 2007 135 143
47. K.L. Eskow, K.B. Dupre, and C.J. Barnum The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats Synapse 63 2009 610 620
48. M. Gerlach, J. Beck, and P. Riederer Flibanserin attenuates L-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease J Neural Transm 118 2011 1727 1732
49. Y. Tani, A. Ogata, and M. Koyama Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats Eur J Pharmacol 649 2010 218 223
50. M.M. Iravani, K. Tayarani-Binazir, and W.B. Chu In 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability J Pharmacol Exp Ther 319 2006 1225 1234
51. F. Bibbiani, J.D. Oh, and T.N. Chase Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 2001 1829 1834
52. K. Kannari, H. Yamato, and H. Shen Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation J Neurochem 76 2001 1346 1353
53. M.J. Jackson, G. Al-Barghouthy, and R.K. Pearce Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets Pharmacol Biochem Behav 79 2004 391 400
54. T. Carlsson, M. Carta, and C. Winkler Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease J Neurosci 27 2007 8011 8022
55. T. Carlsson, M. Carta, and A. Munoz Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration Brain 132 2009 319 335
56. J. Garcia, T. Carlsson, and M. Dobrossy Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia Neurobiol Dis 43 2011 576 587
57. R. Gebhard, K. Zilles, and A. Schleicher Distribution of seven major neurotransmitter receptors in the striate cortex of the New World monkey Callithrix jacchus Neuroscience 56 1993 877 885
58. M. Kraemer, K. Zilles, and A. Schleicher Quantitative receptor autoradiography of eight different transmitter-binding sites in the hippocampus of the common marmoset, Callithrix jacchus Anat Embryol (Berl) 191 1995 213 225
59. M. Politis, K. Wu, and C. Loane Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants Sci Transl Med 2 38 2010 38ra46
60. M. Politis, W.H. Oertel, and K. Wu Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio Mov Disord. 26 2011 1997 2003
61. S.J. Kish, J. Tong, and O. Hornykiewicz Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain 131 2008 120 131
62. L. Gregoire, P. Samadi, and J. Graham Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys Parkinsonism Relat Disord 15 2009 445 452
63. C.W. Olanow, P. Damier, and C.G. Goetz Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study) Clin Neuropharmacol 27 2004 58 62
64. W. Bara-Jimenez, F. Bibbiani, and M.J. Morris Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease Mov Disord 20 2005 932 936
65. C.G. Goetz, P. Damier, and C. Hicking Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov Disord 22 2007 179 186
66. M. Carta, T. Carlsson, and A. Munoz Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias Prog Brain Res 172 2008 465 478
67. V. Bonifati, E. Fabrizio, and R. Cipriani Buspirone in levodopa-induced dyskinesias Clin Neuropharmacol 17 1994 73 82
68. B. Kleedorfer, A.J. Lees, and G.M. Stern Buspirone in the treatment of levodopa induced dyskinesias J Neurol Neurosurg Psychiatry 54 1991 376 377
69. G. Meco, E. Fabrizio, and S. Di Rezze Mirtazapine in L-dopa-induced dyskinesias Clin Neuropharmacol 26 2003 179 181
70. F. Durif, M. Vidailhet, and F. Assal Low-dose clozapine improves dyskinesias in Parkinson's disease Neurology 48 1997 658 662
71. F. Durif, B. Debilly, and M. Galitzky Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study Neurology 62 2004 381 388
72. K. Kannari, K. Kurahashi, and M. Tomiyama Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease No To Shinkei 54 2002 133 137
73. G. Meco, P. Stirpe, and F. Edito Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study J Neural Transm 116 2009 881 884
74. A. Munoz, T. Carlsson, and E. Tronci Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model Exp Neurol 219 2009 298 307
75. M.A. Cenci, K.E. Ohlin, and D. Rylander Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia Parkinsonism Relat Disord 15 Suppl. 3 2009 S59 S63
76. G. Linazasoro New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity Trends Pharmacol Sci 26 2005 391 397